Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Feb 02, 2021 8:56pm
71 Views
Post# 32454493

RE:RE:Sermonizer VS Whinersssssssssssssssssssss

RE:RE:Sermonizer VS Whinersssssssssssssssssssss

that's the risk with all drug developments. I like the fact our toxin is known and it's heavily about the target effectiveness and other aspects.  No doubt it's hard.  But I like we have 4 shots on goal in cancer, 2 in NASH if we include HIV, 2 shots to get revenues up and 1 shot with a new Egifta formula and Trogarzo Push. That's a lot of shots on goal even though some face similar development risks.   They should talk that way in their presentation.  It was the highlight slide for the Texas company Bucknelly posted this morning.  


scarlet1967 wrote: And what if oncology hit the brick wall, although no value has been ascribed to the program as mentioned earlier the stock hasn't had any problem reacting to bad news therefore I would be more comparable if the SP was much higher during that trial.Some might don't mind loosing money or not making money during a bull market well I absolutely DO.
 

palinc2000 wrote: but at least we now know that if phase 3 trials are successful in Nash and oncology the SP will go to the moon,
I feel much better now,,,,

Disclosure
I am long this stock and have no relation whatsoever with anyone working at TH past or present




<< Previous
Bullboard Posts
Next >>